Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lexeo Therapeutics, Inc. (LXEO : NSDQ)

• Company Description    Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $5.11 Daily Weekly Monthly 20 Day Moving Average: 752,406 shares Shares Outstanding: 78.52 (millions) Market Capitalization: $401.25 (millions) Beta: 1.52 52 Week High: $10.99 52 Week Low: $2.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.97% -19.13% 12 Week -25.94% -31.54% Year To Date -48.54% -51.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 345 PARK AVENUE SOUTH FLOOR 6 - NEW YORK,NY 10010 USA ph: 212-547-9879 fax: - investors@lexeotx.com http://www.lexeotx.com

• General Corporate Information    Officers R. Nolan Townsend - Chief Executive Officer and Director Louis Tamayo - Chief Financial Officer Mette Kirstine - Director Steven Altschuler - Director Paula HJ Cholmondeley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 52886X107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 78.52 Most Recent Split Date: (:1) Beta: 1.52 Market Capitalization: $401.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.73 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 74.75% vs. Previous Quarter: 7.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -47.48 12/31/25 - -67.33 09/30/25 - -90.49 ROA 03/31/26 - -41.72 12/31/25 - -55.98 09/30/25 - -70.86 Current Ratio 03/31/26 - 14.16 12/31/25 - 11.21 09/30/25 - 7.40 Quick Ratio 03/31/26 - 14.16 12/31/25 - 11.21 09/30/25 - 7.40 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 2.95 12/31/25 - 3.38 09/30/25 - 2.20 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.09 12/31/25 - 0.13 09/30/25 - 0.37

Powered by Zacks Investment Research ©